Latham & Watkins advised Neumora, and Cooley advised the underwriters. Neumora Therapeutics, Inc. announced the pricing of its initial public offering of 14,710,000 shares of its common…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
